Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence

American Journal of Transplantation

Volumn 7, Issue 10, 2007, Pages 2350-2360

  Hiremath, S ^a   Fergusson, D ^a   Doucette, S ^a   Mulay, A V ^a   Knoll, G A ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Kidney transplantation; Meta analysis; Randomized trial; Systematic review

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; POTASSIUM;

ANEMIA; BLOOD PRESSURE; CLINICAL TRIAL; DRUG MECHANISM; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOCRIT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HEMATOCRIT; HUMANS; KIDNEY TRANSPLANTATION; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 34548301629     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01928.x     Document Type: Review

References (56)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993 329 : 1456 1462.
2. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001 135 : 73 87.
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 342 : 145 153.
4. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 43 : S1 S290.
5. Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004 4 : 262 269.
6. Worner KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 2000 20 : 126 147.
7. Halloran P. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002 2 : 195 200.
8. Seron D, Moresco F, Grinyo JM. Prevention and management of late renal allograft dysfunction. J Nephrol 2001 14 : 71 79.
9. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int 2003 63 : 1187 1194.
10. Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001 72 : 1787 1792.
11. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004 351 : 585 592.
12. Philipp T, Legendre C, Geiger H et al. Study on the evaluation of candesartan cilexetil after renal transplantation (SECRET-Study). Kidney Blood Press Res 2004 27 : 267 423 Abstract)
13. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996 17 : 1 12.
14. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In : Egger M, Davey Smith G, Altman DG. ed S. Systematic reviews in health care. London : BMJ Publishing Group, 2001 : 285 312.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 188.
16. Thompson SG, Higgins J. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002 21 : 1559 1573.
17. el Agroudy AE, Hassan NA, Foda MA et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003 23 : 300 306.
18. Suwelack B, Kobelt V, Erfmann M et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003 16 : 313 320.
19. Cieciura T, Senatorski G, Rell K et al. Influence of angiotensin- converting enzyme inhibitor treatment of the carotid artery intima-media complex in renal allograft recipients. Transplant Proc 2000 32 : 1335 1336.
20. Hernandez D, Lacalzada J, Salido E et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 2000 58 : 889 897.
21. Beckingham IJ, Woodrow G, Hinwood M et al. A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant 1995 10 : 2316 2320.
22. Hernandez E, Morales JM, Andres A et al. Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. Transplant Proc 1995 27 : 2239 2241.
23. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993 43 : 419 425.
24. Gronhagen-Riska C, Fyhrquist F, Ahonen J, von Willebrand E, Hayry P. Angiotensin I-converting enzyme inhibition after renal transplantation. Scand J Urol Nephrol Suppl 1984 79 : 63 67.
25. Ok E, Akcicek F, Toz H et al. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. Transplantation 1995 59 : 1623 1626.
26. Takahara S, Moriyama T, Kokado Y et al. Randomized prospective study of effects of benazepril in renal transplantation: An analysis of safety and efficacy. Clin Exp Nephrol 2002 6 : 242 247.
27. Andres A, Morales E, Morales JM et al. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: A randomized multicenter study. Transplant Proc 2006 38 : 2419 2423.
28. Formica RN, Jr., Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006 21 : 1389 1394.
29. Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993 3 : 1570 1574.
30. Inigo P, Campistol JM, Lario S et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001 12 : 822 827.
31. Martinez-Castelao A, Hueso M, Sanz V et al. Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. Transplant Proc 2002 34 : 403 406.
32. Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995 26 : 436 444.
33. Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post-renal transplant erythrocytosis. Ren Fail 2003 25 : 77 86.
34. Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Rutkowski B. Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. Transplantation 2006 81 : 52 56.
35. Van Der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995 25 : 77 81.
36. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: Synthesis of best evidence for clinical decisions. Ann Intern Med 1997 126 : 376 380.
37. Egger M, Smith GD. Meta-analysis: Potentials and promise. BMJ 1997 315 : 1371 1374.
38. Greenhalgh T. How to read a paper: The basics of evidence-based medicine, 3rd Ed. Blackwell Publishing 2006.
39. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002 347 : 1256 1261.
40. Aull MJ. Chronic allograft nephropathy: Pathogenesis and management of an important posttransplant complication. Prog Transplant 2004 14 : 82 88.
41. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: Fact or fiction. Pharmacotherapy 2003 23 : 788 801.
42. Tylicki L, Habicht A, Watschinger B, Horl WH. Treatment of hypertension in renal transplant recipients. Curr Opin Urol 2003 13 : 91 98.
43. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001 285 : 2719 2728.
44. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 345 : 861 869.
45. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 345 : 851 860.
46. Rigatto C. Management of cardiovascular disease in the renal transplant recipient. Cardiol Clin 2005 23 : 331 342.
47. Shah N, Al Khoury S, Afzali B et al. Posttransplantation anemia in adult renal allograft recipients: Prevalence and predictors. Transplantation 2006 81 : 1112 1118.
48. Vanrenterghem Y, Ponticelli C, Morales JM et al. Prevalence and management of anemia in renal transplant recipients: A European survey.[see comment]. Am J Transplant 2003 3 : 835 845.
49. Formica RN, Jr., Friedman AL, Lorber MI, Bia MJ. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period. Transplant Proc 2004 36 : 2675 2678.
50. Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002 73 : 783 788.
51. Molnar MZ, Novak M, Ambrus C et al. Anemia in kidney transplanted patients. Clin Transplant 2005 19 : 825 833.
52. Afzali B, Al Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after renal transplantation. Am J Kidney Dis 2006 48 : 519 536.
53. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002 13 : 1084 1090.
54. Roodnat JI, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001 72 : 438 444.
55. Fernandez-Fresnedo G, Escallada R, Rodrigo E et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002 73 : 1345 1348.
56. Halimi JM, Laouad I, Buchler M et al. Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005 5 : 2281 2288.